IQ-AI Ltd (LSE:IQAI, FRA:5Y1, OTCQB:IQAIF) said it sold multiple licences for its Imaging Biometrics (IB) software for the automated generation of quantitative perfusion maps.
The sales include renewal licenses for established clients and a new installation of its brain tumour imaging platform IB Clinic at the Eastern Alabama Medical Center (EAMC).
The IB Clinic-Container edition, which includes all the IB software modules, is an automated processing pipeline that frees up neuro radiologists and MR technologists and provides unique information in the diagnosis and treatment of brain tumour patients, IQ-AI said in a statement.
The quantitative capabilities of IB software allow for a standardised imaging protocol across sites and platforms, which means that a patient scanned on one MR scanner can have a follow-up scan on a different MR scanner and the data, if processed with IB Neuro, will be directly comparable. Quantitatively assessing how a tumour is changing over time is critical for both clinicians and their patients, the company said.
"While the pandemic negatively impacted sales earlier this year, we are grateful for the rapid return of sales activity as well as trial evaluations of our software," said Michael Schmainda, CEO of IQ-AI subsidiary IB.
Dr Matthew Dobbs, MD, a radiologist at EAMC said: "We have been using IB quantitative perfusion imaging for over a year at our main cancer centre and the information has been invaluable to us in determining brain tumour treatment planning and follow-up."